Astellas/Boehringer Get Flomax Market Exclusivity Extension Through Pediatric Study
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Astellas Pharma announced that U.S. marketing partner Boehringer Ingelheim has obtained six-month pediatric exclusivity for blockbuster benign prostate hyperplasia drug Flomax (tamsulosin). The Flomax substance patent expires in October, and the period of market exclusivity will now be extended to April 2010